BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mehnert JM, Monjazeb AM, Beerthuijzen JMT, Collyar D, Rubinstein L, Harris LN. The Challenge for Development of Valuable Immuno-oncology Biomarkers. Clin Cancer Res 2017;23:4970-9. [PMID: 28864725 DOI: 10.1158/1078-0432.CCR-16-3063] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Roberts J, Salaria SN, Cates J, Wang Y, Vnencak-Jones C, Berlin J, Shi C. PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes. Am J Clin Pathol 2019;152:384-91. [PMID: 31152546 DOI: 10.1093/ajcp/aqz052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
2 Heydt C, Rehker J, Pappesch R, Buhl T, Ball M, Siebolts U, Haak A, Lohneis P, Büttner R, Hillmer AM, Merkelbach-Bruse S. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. Sci Rep 2020;10:11387. [PMID: 32647293 DOI: 10.1038/s41598-020-68394-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
3 Rosato RR, Dávila-González D, Choi DS, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. Breast Cancer Res 2018;20:108. [PMID: 30185216 DOI: 10.1186/s13058-018-1037-4] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
4 Nielsen TJ, Ring BZ, Seitz RS, Hout DR, Schweitzer BL. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon 2021;7:e06438. [PMID: 33748492 DOI: 10.1016/j.heliyon.2021.e06438] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Qin SK, Li Q, Ming Xu J, Liang J, Cheng Y, Fan Y, Jiang J, Ye H, Tao H, Li L, Zheng L, Wei Z, Li S, Meng K, Ye B, Sun Y. Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. Cancer Sci. 2020;111:4218-4231. [PMID: 32889778 DOI: 10.1111/cas.14641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Lim SM, Hong MH, Kim HR. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Netw 2020;20:e10. [PMID: 32158598 DOI: 10.4110/in.2020.20.e10] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 14.5] [Reference Citation Analysis]
7 Marshall HT, Djamgoz MBA. Immuno-Oncology: Emerging Targets and Combination Therapies. Front Oncol. 2018;8:315. [PMID: 30191140 DOI: 10.3389/fonc.2018.00315] [Cited by in Crossref: 134] [Cited by in F6Publishing: 125] [Article Influence: 33.5] [Reference Citation Analysis]
8 Indini A, Rijavec E, Ghidini M, Tomasello G, Cattaneo M, Barbin F, Bareggi C, Galassi B, Gambini D, Grossi F. Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. Int J Mol Sci 2021;22:2628. [PMID: 33807855 DOI: 10.3390/ijms22052628] [Reference Citation Analysis]
9 Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, Razak ARA, Siu LL, Bedard PL. Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. Oncologist 2019;24:e518-25. [PMID: 30833487 DOI: 10.1634/theoncologist.2018-0808] [Reference Citation Analysis]
10 Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clin Cancer Res 2017;23:4980-91. [PMID: 28864726 DOI: 10.1158/1078-0432.CCR-16-3064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
11 Brown E, Brunker J, Bohndiek SE. Photoacoustic imaging as a tool to probe the tumour microenvironment. Dis Model Mech 2019;12:dmm039636. [PMID: 31337635 DOI: 10.1242/dmm.039636] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
12 Fatima S, Ma Y, Safrachi A, Haider S, Spring KJ, Vafaee F, Scott KF, Roberts TL, Becker TM, de Souza P. Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers 2022;14:1669. [DOI: 10.3390/cancers14071669] [Reference Citation Analysis]
13 Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer 2022;10:e003231. [PMID: 35022192 DOI: 10.1136/jitc-2021-003231] [Reference Citation Analysis]
14 Anagnostou V, Yarchoan M, Hansen AR, Wang H, Verde F, Sharon E, Collyar D, Chow LQM, Forde PM. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. Clin Cancer Res 2017;23:4959-69. [PMID: 28864724 DOI: 10.1158/1078-0432.CCR-16-3065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
15 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
16 Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 2021;12:775761. [PMID: 34925348 DOI: 10.3389/fimmu.2021.775761] [Reference Citation Analysis]
17 Garrido P, Conde E, de Castro J, Gómez-Román JJ, Felip E, Pijuan L, Isla D, Sanz J, Paz-Ares L, López-Ríos F. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 2020;22:989-1003. [PMID: 31598903 DOI: 10.1007/s12094-019-02218-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
18 Shen YC, Yeh CP, Jeng YM, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Cheng AL. Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy. Cancers (Basel) 2021;13:5142. [PMID: 34680292 DOI: 10.3390/cancers13205142] [Reference Citation Analysis]
19 Wang D, Sun K, Wang T, Zhang D, Sun F, Cui Y, Zhao H, Wu J. Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma. Front Pharmacol 2021;12:710943. [PMID: 34867321 DOI: 10.3389/fphar.2021.710943] [Reference Citation Analysis]
20 Enfield KSS, Martin SD, Marshall EA, Kung SHY, Gallagher P, Milne K, Chen Z, Nelson BH, Lam S, English JC, MacAulay CE, Lam WL, Guillaud M. Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. J Immunother Cancer 2019;7:13. [PMID: 30651131 DOI: 10.1186/s40425-018-0488-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
21 Lee E, Lee JW, Lee B, Park K, Shim J, Yoo KH, Koo HH, Sung KW, Park WY. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma. BMC Med Genomics 2020;13:171. [PMID: 33172452 DOI: 10.1186/s12920-020-00819-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Higenell V, Fajzel R, Batist G, Cheema PK, McArthur HL, Melosky B, Morris D, Petrella TM, Sangha R, Savard MF, Sridhar SS, Stagg J, Stewart DJ, Verma S. A network approach to developing immuno-oncology combinations in Canada. Curr Oncol 2019;26:73-9. [PMID: 31043804 DOI: 10.3747/co.26.4393] [Reference Citation Analysis]
23 Wang A, Chu H, Jin Z, Gong Z, Jia Q, Zhu B. ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. Cancer Med 2021. [PMID: 34862755 DOI: 10.1002/cam4.4475] [Reference Citation Analysis]
24 Hoyt CC. Multiplex Immunofluorescence and Multispectral Imaging: Forming the Basis of a Clinical Test Platform for Immuno-Oncology. Front Mol Biosci 2021;8:674747. [PMID: 34150850 DOI: 10.3389/fmolb.2021.674747] [Reference Citation Analysis]
25 Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review. Front Oncol 2020;10:585311. [PMID: 33643899 DOI: 10.3389/fonc.2020.585311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
26 Baik CS, Rubin EH, Forde PM, Mehnert JM, Collyar D, Butler MO, Dixon EL, Chow LQM. Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. Clin Cancer Res 2017;23:4992-5002. [PMID: 28864727 DOI: 10.1158/1078-0432.CCR-16-3066] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
27 Siu LL, Ivy SP, Dixon EL, Gravell AE, Reeves SA, Rosner GL. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. Clin Cancer Res 2017;23:4950-8. [PMID: 28864723 DOI: 10.1158/1078-0432.CCR-16-3079] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
28 Sprooten J, Vankerckhoven A, Vanmeerbeek I, Borras DM, Berckmans Y, Wouters R, Laureano RS, Baert T, Boon L, Landolfo C, Testa AC, Fischerova D, Van Holsbeke C, Bourne T, Chiappa V, Froyman W, Schols D, Agostinis P, Timmerman D, Tejpar S, Vergote I, Coosemans A, Garg AD. Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. J Immunother Cancer 2021;9:e003609. [PMID: 34795003 DOI: 10.1136/jitc-2021-003609] [Reference Citation Analysis]
29 Leng Y, Dang S, Yin F, Gao T, Xiao X, Zhang Y, Chen L, Qin C, Lai N, Zhan XY, Huang K, Luo C, Kang Y, Wang N, Li Y, Liang Y, Huang B. GDPLichi: a DNA Damage Repair-Related Gene Classifier for Predicting Lung Adenocarcinoma Immune Checkpoint Inhibitors Response. Front Oncol 2021;11:733533. [PMID: 34970479 DOI: 10.3389/fonc.2021.733533] [Reference Citation Analysis]
30 Liu J, Kang R, Kroemer G, Tang D. Targeting HSP90 sensitizes pancreas carcinoma to PD-1 blockade. OncoImmunology 2022;11:2068488. [DOI: 10.1080/2162402x.2022.2068488] [Reference Citation Analysis]
31 Hopkins A, Jaffee E. Pancreatic cancer: Next-generation algorithms for neoantigen selection. Nat Rev Gastroenterol Hepatol 2018;15:135-6. [PMID: 29317775 DOI: 10.1038/nrgastro.2017.184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Shimada Y, Okuda S, Watanabe Y, Tajima Y, Nagahashi M, Ichikawa H, Nakano M, Sakata J, Takii Y, Kawasaki T, Homma KI, Kamori T, Oki E, Ling Y, Takeuchi S, Wakai T. Histopathological characteristics and artificial intelligence for predicting tumor mutational burden-high colorectal cancer. J Gastroenterol 2021;56:547-59. [PMID: 33909150 DOI: 10.1007/s00535-021-01789-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Gou Q, Xie Y, Zhang M, Chen Y, Shen Y. Synchronous Rectal Tumours with Different Molecular and Genetic Phenotypes Occurring in a Patient with Lynch Syndrome. Cancer Manag Res 2021;13:8009-15. [PMID: 34707409 DOI: 10.2147/CMAR.S333690] [Reference Citation Analysis]
34 Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, Rebhun RB, Hartigan-O'Connor DJ, Méndez-Lagares G, Tarantal AF, Isseroff RR, Griffith TS, Schalper KA, Merleev A, Saha A, Maverakis E, Kelly K, Aljumaily R, Ibrahimi S, Mukherjee S, Machiorlatti M, Vesely SK, Longo DL, Blazar BR, Canter RJ, Murphy WJ, Monjazeb AM. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med 2019;25:141-51. [PMID: 30420753 DOI: 10.1038/s41591-018-0221-5] [Cited by in Crossref: 207] [Cited by in F6Publishing: 216] [Article Influence: 51.8] [Reference Citation Analysis]
35 Kato K, Doki Y, Ura T, Hamamoto Y, Kojima T, Tsushima T, Hironaka S, Hara H, Kudo T, Iwasa S, Muro K, Yasui H, Minashi K, Yamaguchi K, Ohtsu A, Kitagawa Y. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer. Cancer Sci 2020;111:1676-84. [PMID: 32160365 DOI: 10.1111/cas.14380] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
36 Liu C, Wang S, Zheng S, Xu F, Cao Z, Feng X, Wang Y, Xue Q, Sun N, He J. Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer. Front Immunol 2021;12:782106. [PMID: 34868057 DOI: 10.3389/fimmu.2021.782106] [Reference Citation Analysis]
37 Trotta AM, Pacelli R, Scala S. Predictive immune biomarkers: an unattainable chimera? Cell Mol Immunol 2018;15:740-2. [PMID: 29400708 DOI: 10.1038/cmi.2017.162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 2019;4:e000442. [PMID: 30792906 DOI: 10.1136/esmoopen-2018-000442] [Cited by in Crossref: 109] [Cited by in F6Publishing: 97] [Article Influence: 36.3] [Reference Citation Analysis]
39 Hwang S, Kwon AY, Jeong JY, Kim S, Kang H, Park J, Kim JH, Han OJ, Lim SM, An HJ. Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep 2020;10:643. [PMID: 31959763 DOI: 10.1038/s41598-019-57218-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 18.5] [Reference Citation Analysis]